A detailed history of 111 Capital transactions in Geron Corp stock. As of the latest transaction made, 111 Capital holds 14,756 shares of GERN stock, worth $25,675. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,756
Holding current value
$25,675
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Mar 18, 2025

BUY
$3.3 - $4.44 $48,694 - $65,516
14,756 New
14,756 $52.2 Million

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $657M
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track 111 Capital Portfolio

Follow 111 Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 111 Capital, based on Form 13F filings with the SEC.

News

Stay updated on 111 Capital with notifications on news.